Safety and efficacy of REP 2139-Mg in patients with HDV-related advanced liver disease in an international compassionate access program.
Stern C, Loustaud-Ratti V, Yurdaydin C, Brancaccio G, Jachs M, Reiberger T, Bardou-Jacquet E, Metivier S, Alric L, Colombain L, Meszaros M, Mathurin P, Yardeni D, Etzion O, Neumann-Haefelin C, Douglas M, Poulin S, Bazinet M, Metin RO, Vitale A, Gaeta GB, Schwarz M, Ben-Ali S, Bedoya JU, Testoni B, Zoulim F, Plissonnier ML, Levrero M, Paradis V, Francois S, de Freitas C, Kaysin F, Lecomte L, Morvan C, Schramko J, Bondezi K, Baril MÉ, Brichler S, Gerber A, Gordien E, Mackiewicz V, Dahari H, Svicher V, Chevaliez S, Vaillant A, Bourliere M.
Stern C, et al. Among authors: loustaud ratti v.
J Hepatol. 2025 Nov 6:S0168-8278(25)02612-1. doi: 10.1016/j.jhep.2025.10.029. Online ahead of print.
J Hepatol. 2025.
PMID: 41205755